Literature DB >> 23374903

[Oral glucocorticoid-induced psychiatric side-effects: focus on clinical specificities, incidence, risk factors and treatment].

A Ricoux1, M Guitteny-Collas, A Sauvaget, P Delvot, P Pottier, M Hamidou, J-M Vanelle.   

Abstract

Oral glucocorticoids have been used for several decades and psychiatric side-effects may occur. This review will discuss relevant data of the clinical specificities, the incidence, the risk factors for the occurrence of these episodes and the preventive and curative medications of these episodes. We performed a literature review by using PubMed database. We selected and discussed articles and studies with high standard of evidence. The occurrence of psychiatric symptoms is quite frequent. The varying intensity of clinical features ranges from minor signs (impregnation) to acute psychotic episodes which may occur from 5 to 30% of patients. Affective symptoms or disorders are the most prominent clinical features. Delirium may occur and suicidal risk could be increased. The significant predictive factors are prednisone dosage more than 40 mg/day, particularly weight-based dosage, and a history of psychiatric disorders. When a reduced dosage of glucocorticoids is not sufficient to control the symptomatology, curative medication is mainly based on atypical antipsychotics such as olanzapine. Studies about neuropsychiatric complications of glucocorticoids present various and heterogeneous results. Further prospective clinical studies should be based on a close cooperation between physicians and consultation liaison psychiatrists. This collaboration is required for an optimized management of the patient who receive glucocorticoids.
Copyright © 2012 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23374903     DOI: 10.1016/j.revmed.2012.12.011

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  6 in total

1.  [Factors associated with mental disorders in the psychiatric department of the university hospital centre of Point G in Mali.]

Authors:  S P Coulibaly; F I Maïga; G Landouré; H Dolo; P P Mounkoro; A E Dara; J Traoré; K Traoré; F Kané; Z Diarra; A Yalcouyé; A Taméga; A Bocoum; S Coulibaly; C O Guinto; A Togora
Journal:  Mali Med       Date:  2021-04-19

Review 2.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

3.  SNI case of the week: Initial concomitant use of gabapentin, clonidine, and prednisone may enhance suicidal ideation: A case report.

Authors:  Ramsis F Ghaly; Ana Plesca; Kenneth D Candido; Nebojsa Nick Knezevic
Journal:  Surg Neurol Int       Date:  2020-03-06

4.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

5.  Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man.

Authors:  K Kalafatakis; G M Russell; C J Harmer; M R Munafo; N Marchant; A Wilson; J C Brooks; C Durant; J Thakrar; P Murphy; N J Thai; S L Lightman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

Review 6.  Dynamics of ACTH and Cortisol Secretion and Implications for Disease.

Authors:  Stafford L Lightman; Matthew T Birnie; Becky L Conway-Campbell
Journal:  Endocr Rev       Date:  2020-06-01       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.